Pfizer reports that the FDA has  approved a supplemental New Drug Application for XALKORI® (crizotinib) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.

In 2015, the FDA granted Breakthrough Therapy and Priority Review designations for this indication.

XALKORI also is indicated for patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.